BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 22560970)

  • 21. Usefulness of 18F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: a meta-analysis.
    Tang S; Huang G; Liu J; Liu T; Treven L; Song S; Zhang C; Pan L; Zhang T
    Eur J Radiol; 2011 Apr; 78(1):142-50. PubMed ID: 19854016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of F-18 fluorodeoxyglucose positron emission tomography with dual-phase imaging to identify intraductal papillary mucinous neoplasm.
    Saito M; Ishihara T; Tada M; Tsuyuguchi T; Mikata R; Sakai Y; Tawada K; Sugiyama H; Kurosawa J; Otsuka M; Uchida Y; Uchiyama K; Miyazaki M; Yokosuka O
    Clin Gastroenterol Hepatol; 2013 Feb; 11(2):181-6. PubMed ID: 23142206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The usefulness of (18)F-FDG PET/MRI fusion image in diagnosing pancreatic tumor: comparison with (18)F-FDG PET/CT.
    Nagamachi S; Nishii R; Wakamatsu H; Mizutani Y; Kiyohara S; Fujita S; Futami S; Sakae T; Furukoji E; Tamura S; Arita H; Chijiiwa K; Kawai K
    Ann Nucl Med; 2013 Jul; 27(6):554-63. PubMed ID: 23580090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MDCT imaging findings for characterization pancreatic cystic lesion: differentiation between benign and malignant pattern.
    Pongpornsup S; Piyapittayanan S; Charoensak A
    J Med Assoc Thai; 2011 Mar; 94(3):369-78. PubMed ID: 21560846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDG-PET/CT for diagnosis of primary ovarian cancer.
    Kitajima K; Suzuki K; Senda M; Kita M; Nakamoto Y; Onishi Y; Maeda T; Yoshikawa T; Ohno Y; Sugimura K
    Nucl Med Commun; 2011 Jul; 32(7):549-53. PubMed ID: 21407140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT.
    Rahbar K; Seifarth H; Schäfers M; Stegger L; Hoffmeier A; Spieker T; Tiemann K; Maintz D; Scheld HH; Schober O; Weckesser M
    J Nucl Med; 2012 Jun; 53(6):856-63. PubMed ID: 22577239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of International Consensus Guidelines versus 18-FDG PET in detecting malignancy of intraductal papillary mucinous neoplasms of the pancreas.
    Pedrazzoli S; Sperti C; Pasquali C; Bissoli S; Chierichetti F
    Ann Surg; 2011 Dec; 254(6):971-6. PubMed ID: 22076067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
    Li DL; Xu YK; Wang QS; Wu HB; Li HS
    Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules.
    Takanami K; Hiraide T; Tsuda M; Nakamura Y; Kaneta T; Takase K; Fukuda H; Takahashi S
    Ann Nucl Med; 2011 Aug; 25(7):501-10. PubMed ID: 21537945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
    Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
    Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
    Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
    Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Preoperative Imaging Modalities for the Assessment of Malignant Potential of Pancreatic Cystic Lesions: A Network Meta-analysis.
    Lee SW; Shim SR; Jeong SY; Kim SJ
    Clin Nucl Med; 2022 Oct; 47(10):849-855. PubMed ID: 35713890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions--a prospective study with 104 patients.
    Lemke AJ; Niehues SM; Hosten N; Amthauer H; Boehmig M; Stroszczynski C; Rohlfing T; Rosewicz S; Felix R
    J Nucl Med; 2004 Aug; 45(8):1279-86. PubMed ID: 15299049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
    Yildirim H; Metintas M; Entok E; Ak G; Ak I; Dundar E; Erginel S
    J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benign nonphysiologic lesions with increased 18F-FDG uptake on PET/CT: characterization and incidence.
    Metser U; Miller E; Lerman H; Even-Sapir E
    AJR Am J Roentgenol; 2007 Nov; 189(5):1203-10. PubMed ID: 17954662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does 18F-FDG PET/MRI reduce the number of indeterminate abdominal incidentalomas compared with 18F-FDG PET/CT?
    Schaarschmidt BM; Grueneisen J; Heusch P; Gomez B; Umutlu L; Ruhlmann V; Rosenbaum-Krumme S; Antoch G; Buchbender C
    Nucl Med Commun; 2015 Jun; 36(6):588-95. PubMed ID: 25759944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.